Poxel
Advertisement
Poxel is a clinical-stage biopharmaceutical company based in Cambridge, MA, specializing in the development of innovative treatments for chronic serious diseases with metabolic pathophysiology, particularly focusing on non-alcoholic steatohepatitis (NASH) and rare disorders. The company boasts a robust pipeline, including mid-stage products PXL065 and PXL770, as well as the approved product TWYMEEG (Imeglimin), which is marketed for the treatment of type 2 diabetes in Japan.
With a commitment to targeting mitochondrial dysfunction, Poxel aims to offer safer and more effective therapies through its disease-modifying mechanisms of action. The company is supported by a highly experienced clinical and regulatory team, enhancing its capability to successfully develop and commercialize its products.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement